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Abstract
Background: Efficacy and safety profiles by sex and age (6-9 vs 10-12 years) and magnitude and duration of effect
by effect size overall and across the day of lisdexamfetamine dimesylate (LDX) vs placebo were assessed.
Methods: This study enrolled children (6-12 years) with attention-deficit/hyperactivity disorder (ADHD) in an open-
label dose optimization with LDX (30-70 mg/d) followed by a randomized, double-blind, placebo-controlled, 2-way
crossover phase. Post hoc analyses assessed interaction between sex or age and treatment and assessed effect
sizes for Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) and Permanent Product Measure of Performance
(PERMP) scales and ADHD Rating Scale IV measures. No corrections for multiple testing were applied on time
points and subgroup statistical comparisons.
Results: 129 participants enrolled; 117 randomized. Both sexes showed improvement on all assessments at
postdose time points; females showed less impairment than males for SKAMP and PERMP scores in treatment and
placebo groups at nearly all times. Both age groups improved on all assessments at postdose time points. Children
10-12 years had less impairment in SKAMP ratings than those 6-9 years. Treatment-by-sex interactions were
observed at time points for SKAMP-D, SKAMP total, and PERMP scores; no consistent pattern across scales or time
points was observed. LDX demonstrated significant improvement vs placebo, by effect size, on SKAMP-D from
1.5-13 hours postdose. The overall LS mean (SE) SKAMP-D effect size was -1.73 (0.18). In the dose-optimization
phase, common (≥2%) treatment-emergent adverse events (TEAEs) in males were upper abdominal pain,
headache, affect lability, initial insomnia, and insomnia; in females were nausea and decreased weight. During the
crossover phase for those taking LDX, higher incidence (≥2% greater) was observed in males for upper abdominal
pain and insomnia and in females for nausea and headache. Overall incidence of TEAEs in age groups was similar.
Conclusion: Apparent differences in impairment level between sex and age groups were noted. However, these
results support the efficacy of LDX from 1.5 hours to 13 hours postdose in boys and girls with medium to large
effect sizes across the day with some variability in TEAE incidence by sex.
Trial Registration Number: ClinicalTrials.gov Identifier: NCT00500149.
Background
The efficacy and safety of stimulants for the pharmaco-
logic management of attention-deficit/hyperactivity dis-
order (ADHD) is well documented [1,2]. Short-acting
agents for the treatment of ADHD require multiple
daily doses and have the potential for uneven symptom
control [3,4]. After-school activities including sports or
homework may last into later hours of the day, thus
creating a need for long-acting stimulants for symptom
control [3,5]. To address this and other limitations,
novel delivery systems that result in longer durations of
symptom control were developed [4-6].
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US Inc.) is a prodrug stimulant indicated for the treat-
ment of ADHD in children (aged 6 to 12 years), adoles-
cents (aged 13 to 17 years), and in adults. LDX is a
therapeutically inactive molecule. After oral ingestion,
LDX is converted to l-lysine and active d-amphetamine,
which is responsible for the therapeutic effect [7]. In a
4-week, randomized, placebo-controlled, forced-dose
titration trial in children with ADHD, LDX was admi-
nistered in the morning with a median time of dose
administration between 7:30 AM and 8:00 AM. LDX
demonstrated efficacy versus placebo in improving
ADHD symptoms by symptom ratings and global assess-
ments from the first week of treatment through the end
of the study [8]. In that study, LDX was well tolerated
with a safety profile consistent with that of long-acting
stimulant use. The most common adverse events (AEs)
associated with LDX included decreased appetite,
insomnia, abdominal pain, and irritability [8].
The onset and duration of efficacy of LDX in children
was initially evaluated beginning 1 hour postdose and
ending 12 hours postdose with significant efficacy
shown from 2 to 12 hours [9]. A subsequent laboratory
school study in children with ADHD evaluated onset
and duration of efficacy from 1.5 to 13 hours postdose
as measured by Swanson, Kotkin, Agler, M-Flynn, and
Pelham (SKAMP) total and subscale scores. These
results have been published elsewhere [10]. AEs in this
study were consistent with those observed in other
pediatric studies of LDX [8,9] with the exception of a
higher-than-typically-seen increase in pulse at 12.5
hours postdose for the participants receiving 70 mg/d
LDX [10].
LDX has been shown to be generally effective for
treating ADHD symptoms across the day. Despite this,
little is known about the moderating effects of age and
sex on treatment response to LDX or other stimulants,
and existing studies report mixed results [11]. Results
from the Multimodal Treatment Study of Children With
ADHD (MTA), a large community-based trial of chil-
dren 7.0 to 9.9 years of age, indicated an overall lack of
a moderating effect of sex on treatment response
[12,13]. However, an analysis of data from the Compari-
son of Methylphenidates in an Analog Classroom Set-
ting (COMACS) study, a classroom analog study of
children 6 to 12 years of age, found that females had a
stronger response to methylphenidate from 1.5 to 3.0
hours postdose; from 4.5 to 6.0 hours, responses in
males and females were equivalent, whereas from 7.5 to
12 hours, response among females declined more
quickly than among males, leading to better response in
males for those time points [14]. The COMACS study
included 2 active treatment arms, osmotic-release oral
methylphenidate (OROS-MPH) and methylphenidate
extended-release (MPH-ER). Interestingly, although dif-
ferences existed in the efficacy profiles of OROS-MPH
and MPH-ER in the overall group with MPH-ER
demonstrating superiority early in the day and OROS-
MPH demonstrating superiority later in the day [6], the
differences between males and females were indepen-
dent of formulation [14].
Although some differential cognitive functioning has
been found between girls and boys, most studies have
documented little difference between sexes in cognitive
and executive functions while clearly documenting sig-
nificant impairment in these domains in both girls and
boys with ADHD compared to children without ADHD
[15]. Depression and anxiety may be more problematic
in girls than in boys [16], whereas boys with ADHD are
consistently reported to be more disruptive, more com-
m o n l yi n v o l v e di nr u l eb r e a k i n g ,a n dm o r el i k e l yt o
have comorbid disruptive behavior disorders [17,18].
Although the symptoms of ADHD may differ in
patients of various age groups, little is known about dif-
ferences in treatment effects and AEs experienced by
children of different ages within the same study. In a
study of preschool-aged children (3 to 5.5 years of age),
treated with immediate-release methylphenidate in a 70-
week, multiple phase study utilizing both parent and
teacher-rated assessments (the Preschool ADHD Treat-
ment Study [PATS]), factor scores derived from the
Conners, Loney, and Milich scale observed smaller effect
sizes in parent and teacher ratings (0.35 and 0.43,
respectively) than those observed in results from the
MTA study of school-aged children (0.52 and 0.75,
respectively) [19,20]. In addition, the preschoolers in the
PATS showed a higher rate of methylphenidate disconti-
nuation due to spontaneously reported AEs than did
school-aged children in the MTA study (ie, 11% vs <1%)
[21]. In fact, pharmacokinetic differences seem to corro-
borate other variables such as clearance rate contribut-
ing to age-related differences [22]. Although many
factors may have contributed to these differences, they
raise the question of whether certain age groups benefit
more from treatment than do others.
Dosing of stimulants is not generally based on by-
weight guidelines, and younger, smaller children may
receive relatively higher by-weight doses than do older,
larger children. Younger, smaller children may theoreti-
cally be at higher risk for dose-dependent AEs. This
possibility is supported by findings that these partici-
pants were prone to higher incidence of some AEs
when receiving the highest dose level in a study of long-
acting methylphenidate [23]. Participants in the PATS
experienced loss of appetite, trouble sleeping, stomach-
aches, social withdrawal, and lethargy, and these AEs
occurred more frequently in participants receiving high-
dose methylphenidate than in those receiving low-dose
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may be more likely to experience sleep difficulties and
decreased appetite as AEs with stimulant treatment at
high dose levels [23].
The post hoc analyses presented here assessed the
efficacy of LDX in female and male participants and
in younger (6 to 9 years) and older (10 to 12 years)
participants to determine whether sex or age interac-
tions were present. The safety profile of LDX was
further characterized by examining AEs by sex and
age. Also assessed was the duration of efficacy of LDX
in a laboratory school setting based on effect size cal-
culations for SKAMP and Permanent Product Measure
of Performance (PERMP) measures. Effect size ana-
lyses are a useful method for providing clinically rele-
vant information about the magnitude of effect
relative to the effects of placebo, and where data are
available, effect size assessments provide a systematic
quantitative framework for assessing the relative
effects of therapeutic agents across studies [24]. Effect
size analyses may provide more practical information
about the expected therapeutic effect (eg, efficacy and
tolerability) that can be applied to making therapeutic
choices.
Study objectives
The objective of this post hoc analysis was to examine
the efficacy and safety profile of LDX by sex and age
group in children with ADHD in a laboratory school
setting. This analysis also aimed to assess the magnitude
of effect overall and across the day of LDX vs placebo
based on effect size analysis of SKAMP, PERMP, and
ADHD Rating Scale IV (ADHD-RS-IV) scores.
Methods
This randomized, double-blind, multicenter, placebo-
controlled, dose-optimization, crossover laboratory
school study of LDX was conducted at 7 study sites in
the United States. Full details of the methodological
design and conduct of this study have been previously
published [10]. All study activities were performed in
accordance with the principles of the International Con-
ference on Harmonisation Good Clinical Practice, 18th
World Medical Assembly (Helsinki 1964), and amend-
ments of the 29th (Tokyo 1975), the 35th (Venice 1983),
the 41st (Hong Kong 1989), and the 48th (South Africa
1996) World Medical Assemblies. This was a study of
children (6 to 12 years of age) diagnosed with moderate
to severe ADHD (baseline ADHD-RS-IV score ≥28) and
included a screening and washout (for those participants
taking other medications for ADHD at screening), an
open-label, dose-optimization phase of LDX (30, 50, or
70 mg/d) followed by a randomized, double-blind, pla-
cebo-controlled, 2-way crossover phase (Figure 1). Key
exclusion criteria were the presence of a comorbid psy-
chiatric condition with severe symptoms, conduct disor-
der, or other medical condition that could confound
assessments, pose a risk to the participant, or prohibit
study completion. Other inclusion and exclusion criteria
were detailed previously [10].
Efficacy measures
Efficacy evaluations were performed on the intention-to-
treat population (ITT) population, defined as all
participants who were randomized and had at least 1
SKAMP-Deportment (SKAMP-D) score available after
randomization. Efficacy measures were collected in the
Screening/Washout
Open-Label LDX
Dose-Optimization
Phase
Phase 1  (1 week) Phase 2  (1 week)
Crossover Phases 1 and 2
• Primary diagnosis of ADHD
  with a combined or 
 hyperactive/impulsive  subtype
• Baseline ADHD-RS-IV total 
 score ≥28 Optimal LDX dose 
(30, 50, or 70 mg/d)
n=57
Optimal LDX dose 
(30, 50, or 70 mg/d)
n=58
N=129
R
A
N
D
O
M
I
Z
A
T
I
O
N
 
n
=
1
1
7
Placebo
n=59
Placebo
n=56
Schedule:
• Start: 30 mg/d
• 7 (±2) days: 30 or 50 mg/d
• At 14 (±2) days: 30, 50, or
 70  mg/d
Dosage was increased or
decreased until optimal 
dosage:
• Tolerable AEs
• Reduction of ADHD-RS-IV  
 scores  ≥30%
• CGI-I score of 1 or 2
Figure 1 Study design. Twelve participants discontinued prior to randomization; 4 participants discontinued during the crossover period;
2 participants discontinued after the crossover phase; 9 participants discontinued because of AEs; no participants discontinued because of lack
of efficacy.
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2.5, 5.0, 7.5, 10.0, 12.0, and 13.0 hours postdose during
crossover periods 1 and 2. The primary efficacy outcome
was the onset of efficacy for LDX vs placebo as assessed
by the primary outcome measure, SKAMP-D scores
[10]. Key secondary assessments included the SKAMP-
Attention (SKAMP-A) and SKAMP quality of work sub-
scales, SKAMP total scores, PERMP number attempted
(PERMP-A) and PERMP number correct (PERMP-C),
and the ADHD-RS-IV. SKAMP and PERMP were
assessed predose and 1.5, 2.5, 5.0, 7.5, 10.0, 12.0, and
13.0 hours postdose during crossover periods 1 and 2.
ADHD-RS-IV was administered at baseline and during
each weekly visit.
The SKAMP scale is a validated rating scale that
assesses behavioral symptoms of ADHD in a classroom
setting using a 7-point impairment scale (0 = none, 6 =
maximal impairment) [25,26]. The SKAMP total score
comprises 13 items [26]. The SKAMP-D subscale evalu-
ates deportment, including interacting with other chil-
dren, interacting with adults, remaining quiet according
to classroom rules, and staying seated according to
classroom rules. The SKAMP-A subscale is a measure
of attention and evaluates getting started on assign-
ments, sticking with tasks, attending to an activity, and
making activity transitions. The SKAMP quality of work
subscale includes 3 items: completing assigned work,
performing work accurately, and being careful and neat
while writing or drawing.
The PERMP, a 5-page test consisting of 80 math
problems per page (total of 400 problems) [26], evalu-
ated effortful performance in the classroom as a mea-
sure of efficacy. Participants were instructed to work at
their seats and to complete as many problems as possi-
ble in 10 minutes. The appropriate level of difficulty
for each student was determined previously based on
results of a math pretest administered at screening.
Performance was evaluated using PERMP-A and
PERMP-C scores.
The ADHD-RS-IV [27] is a clinician-rated scale that
reflects current symptoms of ADHD based on Diagnos-
tic and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision (DSM-IV-TR) criteria; it is a glo-
bal assessment that measures the severity of symptoms
from visit to visit, but was not used to assess symptoms
of ADHD over the course of the day. The ADHD-RS-IV
consists of 18 items that are grouped into 2 subscales
(hyperactivity/impulsivity and inattention). Each item is
scored on a scale of 0 (no symptoms) to 3 (severe symp-
toms), yielding a total score of 0 to 54.
Safety assessments
The safety population included all participants who were
enrolled in the dose-optimization phase and received at
least 1 dose of LDX. Treatment-emergent AEs (TEAEs),
referring to events with onset after the first date of
treatment, and no later than 3 days following termina-
tion of treatment, were recorded separately for the dose-
optimization and the double-blind crossover phases of
the study. TEAEs that continued uninterrupted from the
dose-optimization to the crossover phase without a
change in severity were counted only in the dose-
optimization phase category. TEAEs with a change in
severity across phases or that resolved and then restarted
in the crossover phase were counted both in the dose-
optimization and crossover arms. TEAEs for which a
missing or incomplete start date made it impossible to
determine in which phase of the study they started were
counted as starting in the dose-optimization phase.
TEAEs were reported as number and percentage of
participants according to system-organ class, preferred
term, treatment group, and by last dose received at AE
onset. AEs were collected at all visits by soliciting partici-
pant report with nonleading questions, and were coded
using the Medical Dictionary for Regulatory Activities
(MedDRA).
Statistical analyses
Treatment interaction by age and sex were analyzed,
post hoc, among the ITT population using a linear
mixed model with sequence, period, sex (or age), treat-
ment, and treatment by sex (or age) defined as fixed
effects and subject-within-sequence as the random
effect. No corrections for multiple testing were applied
on time points and subgroup statistical comparisons.
Post hoc analyses evaluated SKAMP and PERMP
effect size calculations for different dose groups,
S K A M Pa n dP E R M Ps c o r e sf o rm a l e sa n df e m a l e s ,a n d
demographic data and AEs by age and sex. Least
squares (LS) effect size and standard errors (SEs) were
calculated according to the method of Curtin, Altman,
and Elbourne [28] (standardized weighted mean differ-
ence [SWMD] methodology) at each postdose time
point for SKAMP and PERMP assessments and for
mean SKAMP-D score in the ITT population. The
SWMD considers the treatment effect in relation to
within-group standard deviation (SD) to combine con-
tinuous results of trials to evaluate the effect of treat-
ment [28]. Effect size is a derived statistical assessment
designed to allow comparisons of efficacy across clinical
trials [29]. In general, effect size is calculated as the dif-
ference between drug effects and placebo effects divided
by their pooled SD [29]. There are multiple methods for
assessing pooled variance [28] depending on differences
in the study design of included studies. Based on analy-
sis by Cohen, effect sizes of 0.2, 0.5, and 0.8, respec-
tively, correspond to a small, medium, and large
magnitude of effect [30]. Negative SKAMP effect sizes
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with LDX.
Results
During the dose-optimization phase, 58 participants
were optimized to 30 mg/d LDX, 50 participants to
50 mg/d LDX, and 21 participants to 70 mg/d LDX;
across all groups, participant demographics and charac-
teristics were well balanced (Table 1). Overall demo-
graphic data have been published previously [10].
In the 2-way crossover phase of the study, 129 partici-
pants were enrolled and 117 were randomized. Eighteen
participants discontinued the study with 9 discontinuing
because of AEs. No participant discontinued because of
lack of efficacy of LDX (Figure 1).
Efficacy analyses
Sex analysis
At the predose time point, there were significant effects
of sex for SKAMP-D and SKAMP-A subscale scores
and SKAMP total scores and significant treatment con-
dition effects for SKAMP-A and SKAMP quality of
work subscale scores and SKAMP total scores (Table 2).
There were significant treatment condition effects for
PERMP-A and PERMP-C, and no significant effects of
treatment-by-sex interactions were observed at the pre-
dose time point (Table 2).
Results of efficacy analyses for postdose time points by
sex are shown in Figures 2 and 3 and mixed model sta-
tistical analysis in Table 2. There were significant effects
of sex (P < .05) at all time points for SKAMP-D scores.
For SKAMP-D scores, the only significant treatment-by-
sex interaction was seen at the 7.5-hour time point.
Results of the sex analysis for SKAMP total mirrored
those of SKAMP-D with significant effects at all time
points and a significant treatment-by-sex interaction at
7.5 and 10 hours postdose. For SKAMP-A, significant
effects of sex were seen at only 1 time point (10 hours),
and no significant treatment-by-sex interactions were
observed at any postdose time point. For PERMP-A and
PERMP-C, no significant effects of sex were seen,
although significant treatment-by-sex interactions were
seen at 1 time point (10 hours postdose). With LDX
treatment, LS mean SKAMP scores for females were
lower than those for males for all measures at all time
points. Similarly, LS mean SKAMP scores for females
were lower than those for males for all measures at all
time points when receiving placebo.
Table 1 Participant Demographics (Safety Population)
LDX Dose
Category Age Group Statistic 30 mg/d 50 mg/d 70 mg/d All doses
Age (y) 6-9 n 27 15 6 48
Mean (SD) 8.5 (0.75) 8.5 (0.74) 8.0 (0.89) 8.5 (0.77)
10-12 n 31 35 15 81
Mean (SD) 10.9 (0.96) 10.9 (0.73) 11.4 (1.12) 11.0 (0.91)
Sex* Male 6-9 n (%) 18 (66.7) 13 (86.7) 6 (100) 37 (77.1)
Female n (%) 9 (33.3) 2 (13.3) 0 11 (22.9)
Male 10-12 n (%) 26 (83.9) 24 (68.6) 11 (73.3) 61 (75.3)
Female n (%) 5 (16.1) 11 (31.4) 4 (26.7) 20 (24.7)
Weight (lb) 6-9 n 27 15 6 48
Mean (SD) 62.2 (8.78) 65.0 (13.75) 53.1 (2.50) 61.9 (10.62)
10-12 n 31 35 15 81
Mean (SD) 78.9 (16.36) 79.0 (18.64) 80.7 (17.29) 79.3 (17.34)
Height (in) 6-9 n 27 15 6 48
Mean (SD) 51.2 (2.30) 52.1 (2.29) 49.3 (2.04) 51.3 (2.38)
10-12 n 31 35 15 81
Mean (SD) 56.2 (2.84) 56.2 (3.08) 57.3 (2.79) 56.4 (2.93)
Body mass index (kg/m
2) 6-9 n 27 15 6 48
Mean (SD) 16.6 (1.44) 16.7 (2.38) 15.4 (1.28) 16.5 (1.78)
10-12 n 31 35 15 81
Mean (SD) 17.4 (2.45) 17.4 (2.67) 17.2 (2.55) 17.4 (2.53)
SD: standard deviation.
*Percentages are based on number of participants in the age group of the dose classification.
Wigal et al. Child and Adolescent Psychiatry and Mental Health 2010, 4:32
http://www.capmh.com/content/4/1/32
Page 5 of 17Age analysis
At the predose time point, there were significant effects
of age for SKAMP-D subscale and SKAMP total scores
and significant treatment condition effects for SKAMP-
A subscale, SKAMP quality of work subscale, SKAMP
total scores, PERMP-A, and PERMP-C (Table 3).
Results of efficacy analyses for postdose time points by
age are shown in Figures 4 and 5 and mixed model sta-
tistical analysis in Table 3. There were significant effects
of age at all time points for SKAMP-D subscale scores,
except at the 10-hour time point, with participants aged
10 to 12 years showing less impairment than did those
aged 6 to 9 years overall. Significant treatment-by-age
interactions were seen at the 2.5- and 5-hour time
points.
Results of age analysis for SKAMP total scores were
similar to those of SKAMP-D and showed significant
effects at all postdose time points, with participants
aged 10 to 12 years demonstrating significantly less
impairment than did those aged 6 to 9 years overall and
a significant treatment-by-age interaction at 5 hours.
For SKAMP-A, significant effects of age were seen at all
postdose time points, except at 2.5 hours, and the only
significant treatment-by-age interaction was observed at
the 7.5-hour time point. With LDX treatment, LS mean
SKAMP scores for participants aged 10 to 12 years were
lower than were those for participants aged 6 to 9 years
for all measures at all postdose time points with the
exception of the SKAMP quality of work at the 7.5-hour
time point. Similarly, LS mean SKAMP scores for parti-
c i p a n t sa g e d1 0t o1 2y e a r sw e r el o w e rt h a nt h o s ef o r
participants aged 6 to 9 years for all measures at all
postdose time points when receiving placebo, with the
exception of the SKAMP quality of work subscale at the
1.5-, 10-, and 13-hour postdose time points. No signifi-
cant effects for age were noted in PERMP-A and
Table 2 Mixed Model Analysis by Treatment, Sex, and Treatment by Sex for Predose and Postdose Time Points*
Time Point
(hr)
Mixed Model Statistical
Analysis
SKAMP-D SKAMP-A SKAMP-Total SKAMP-QoL PERMP-A PERMP-C
F
Value
P
Value
F
Value
P
Value
F
Value
P
Value
F
Value
P
Value
F
Value
P
Value
F
Value
P
Value
-0.5 Treatment 0.99 .3230 7.21 .0084 28.52 <.0001 93.12 <.0001 22.19 <.0001 23.58 <.0001
Sex 9.36 .0028 8.71 .0039 13.38 .0004 0.75 .3891 0.31 .5809 0.25 .6164
Treatment by sex 1.95 .1657 0.19 .6620 2.49 .1173 0.52 .4714 0.59 .4447 0.76 .3861
1.5 Treatment 19.58 <.0001 12.45 .0006 28.01 <.0001 1.06 .3049 13.67 .0003 19.73 <.0001
Sex 6.59 .0116 3.50 .0639 7.84 .0060 3.72 .0562 0.37 .5421 0.48 .4899
Treatment by sex 0.00 .9779 0.10 .7528 0.20 .6578 0.88 .3493 0.05 .8245 0.39 .5315
2.5 Treatment 70.77 <.0001 53.15 <.0001 131.44 <.0001 43.18 <.0001 60.11 <.0001 65.68 <.0001
Sex 7.89 .0059 2.35 .1278 8.72 .0038 2.88 .0928 0.39 .5326 0.39 .5350
Treatment by sex 2.71 .1023 0.81 .3708 2.97 .0875 0.15 .6995 1.10 .2975 1.62 .2063
5.0 Treatment 74.56 <.0001 50.75 <.0001 136.60 <.0001 68.23 <.0001 73.30 <.0001 76.40 <.0001
Sex 7.13 .0087 2.58 .1111 7.00 .0093 0.20 .6518 0.23 .6357 0.18 .6708
Treatment by sex 2.50 .1166 1.33 .2517 1.63 .2049 0.28 .5949 1.18 .2801 1.40 .2398
7.5 Treatment 67.32 <.0001 56.67 <.0001 137.48 <.0001 53.75 <.0001 89.27 <.0001 92.70 <.0001
Sex 9.38 .0028 3.52 .0633 11.68 .0009 10.46 .0016 1.65 .2021 1.73 .1916
Treatment by sex 4.31 .0402 2.10 .1506 4.16 .0438 0.24 .6248 0.92 .3406 0.76 .3855
10 Treatment 44.74 <.0001 39.70 <.0001 92.89 <.0001 17.42 <.0001 64.41 <.0001 69.95 <.0001
Sex 8.67 .0039 5.07 .0263 13.35 .0004 3.22 .0754 0.65 .4233 0.69 .4083
Treatment by sex 1.51 .2222 3.67 .0579 6.31 .0135 2.86 .0939 5.43 .0217 4.98 .0277
12 Treatment 21.05 <.0001 30.04 <.0001 69.72 <.0001 26.38 <.0001 47.55 <.0001 52.36 <.0001
Sex 14.36 .0002 2.33 .1299 12.84 .0005 0.67 .4165 0.34 .5613 0.36 .5484
Treatment by sex 0.93 .3374 0.37 .5455 0.55 .4586 0.31 .5767 1.32 .2524 1.42 .2357
13 Treatment 3.70 .0568 19.09 <.0001 21.25 <.0001 8.13 .0052 39.39 <.0001 41.15 <.0001
Sex 12.45 .0006 2.84 .0945 13.56 .0004 1.53 .2187 1.08 .3012 1.37 .2439
Treatment by sex 1.30 .2571 2.69 .1039 3.03 .0844 0.00 .9942 3.58 .0609 2.74 .1006
LDX: lisdexamfetamine dimesylate; PERMP: Permanent Product Measure of Performance; PERMP-A: PERMP-Attempted; PERMP-C: PERMP-Correct; SKAMP: Swanson,
Kotkin, Agler, M-Flynn, and Pelham; SKAMP-A: SKAMP-Attention; SKAMP-D: SKAMP-Deportment.
*Degrees of freedom (df) = 110 for all analyses except the 7.5-hour postdose time point where df = 109 for all analyses.
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tions were noted at the 5-hour time point for both
PERMP-A and PERMP-C measures.
Effect size
The predose LS mean (SE) effect size for the SKAMP-D
subscale was 0.26 (0.13). Based on effect sizes, LDX
demonstrated significant improvement on the SKAMP-
D( P < .05) compared with placebo from 1.5 hours, the
first postdose time point measured, to 13 hours post-
dose, the last time point measured. The LS mean (SE)
treatment effect size over the classroom day on the
SKAMP-D was -1.73 (0.18). The magnitude of effect
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Page 7 of 17size of LDX treatment as measured by the SKAMP-D
subscale was mostly medium to large except for the last
time point (13 hours postdose) at which a small to med-
ium effect was observed (Table 4).
The predose LS mean (SE) effect size for the SKAMP-
A and SKAMP quality of work subscales and SKAMP
total scores were 0.45 (0.14), 1.55 (0.17), and 0.94 (0.15),
respectively. Based on effect sizes for SKAMP-A and
SKAMP total scores, LDX demonstrated improvement
compared with placebo from 1.5 hours to 13 hours
postdose (Table 4); for SKAMP quality of work subscale,
LDX demonstrated improvement compared with pla-
cebo from 2.5 hours to 13 hours postdose (Table 4).
The magnitude of effect size of LDX treatment as
measured by SKAMP subscale scores (SKAMP-D,
SKAMP-A, and SKAMP quality of work) and SKAMP
total score effect sizes demonstrated a medium to large
effect size of drug vs placebo at most postdose time
points (Table 4).
The predose LS mean (SE) effect size for PERMP-A
and PERMP-C scores were -0.79 (0.14) and -0.82 (0.14),
respectively. The postdose effect size of LDX on
PERMP-A and PERMP-C was large and maintained
from 1.5 to 13 hours postdose (Table 4).
The mean raw postdose effect sizes for all optimized
LDX dose groups (30, 50, and 70 mg/d) were mostly
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Page 8 of 17large for SKAMP-D, SKAMP-A, and SKAMP quality of
work subscales, and SKAMP total score (Table 5).
As previously reported, ADHD-RS-IV total score and
ADHD-RS-IV inattention and hyperactivity/impulsivity
subscale scores decreased from baseline for all doses of
LDX during the dose-optimization phase and improved
for all doses of LDX vs placebo (by difference in LS
means: all P < .0001) during the crossover phase [10].
Large treatment effect sizes were observed. The LS
mean (SE) treatment effect size was -1.4 (0.16) for
ADHD-RS-IV total score and -1.4 (0.16) for inattention
and -1.3 (0.16) for hyperactivity/impulsivity subscale
scores.
Safety
Overall safety data have been published previously
[10]. There were no deaths or serious AEs reported
during this study. Most TEAEs were mild to moderate
in severity. During the dose-optimization phase, 110
participants (85.3%) reported TEAEs; the most com-
mon TEAEs reported during this phase included
decreased appetite (47.3%), insomnia (27.1%), headache
(17.1%), irritability (16.3%), affect lability (10.1%), and
upper abdominal pain (15.5%). During the crossover
phase, the most common TEAEs reported for partici-
pants receiving LDX included decreased appetite
(6.1%), headache (5.2%), and insomnia (4.3%). Detailed
vital signs and electrocardiographic (ECG) data were
presented previously [10]. During the dose-optimization
phase, there were small increases in systolic blood pres-
sure (SBP), diastolic blood pressure (DBP), and pulse,
but no dose-related changes were noted. During the
crossover phase, small mean increases in SBP, DBP, and
p u l s ew e r es e e nf o rp a r t i c i p a n t sw h i l et a k i n gL D Xa n d
placebo. No clinically concerning trends in ECG para-
meters were identified.
The overall incidence of TEAEs in each sex was simi-
lar during the dose-optimization phase (Table 6). TEAEs
Table 3 Mixed Model Analysis by Treatment, Age, and Treatment by Age for Predose and Postdose Time Points*
Time Point
(hr)
Mixed Model Statistical
Analysis
SKAMP-D SKAMP-A SKAMP-Total SKAMP-QoL PERMP-A PERMP-C
F
Value
P
Value
F
Value
P
Value
F
Value
P
Value
F
Value
P
Value
F
Value
P
Value
F
Value
P
Value
-0.5 Treatment 3.69 .0574 10.88 .0013 48.67 <.0001 133.44 <.0001 34.98 <.0001 37.63 <.0001
Age 8.65 .0040 3.55 .0623 5.76 .0181 0.95 .3307 1.49 .2251 1.60 .2080
Treatment by age 0.10 .7574 0.72 .3971 0.31 .5771 0.02 .9027 0.20 .6580 0.17 .6793
1.5 Treatment 27.82 <.0001 19.41 <.0001 42.98 <.0001 2.92 .0903 18.95 <.0001 30.00 <.0001
Age 6.83 .0102 6.63 .0113 6.93 .0097 0.03 .8716 0.59 .4430 0.54 .4627
Treatment by age 2.38 .1255 1.91 .1693 2.32 .1307 0.09 .7625 0.49 .4876 0.02 .8854
2.5 Treatment 121.66 <.0001 79.31 <.0001 204.35 <.0001 61.19 <.0001 94.10 <.0001 103.60 <.0001
Age 7.25 .0082 3.70 .0571 7.99 .0056 2.49 .1172 0.14 .7066 0.23 .6303
Treatment by age 5.99 .0159 0.01 .9253 1.93 .1672 0.02 .8971 1.74 .1902 1.27 .2619
5.0 Treatment 126.22 <.0001 79.64 <.0001 213.18 <.0001 89.58 <.0001 117.59 <.0001 122.97 <.0001
Age 5.20 .0245 6.59 .0116 8.64 .0040 2.49 .1173 0.04 .8480 0.07 .7974
Treatment by age 5.57 .0201 0.49 .4865 4.54 .0353 2.72 .1018 4.41 .0379 4.25 .0415
7.5 Treatment 109.78 <.0001 98.23 <.0001 215.28 <.0001 76.54 <.0001 134.00 <.0001 137.53 <.0001
Age 5.27 .0236 6.93 .0097 7.27 .0081 0.00 .9885 0.21 .6473 0.35 .5544
Treatment by age 0.12 .7342 6.55 .0118 2.06 .1543 0.06 .8090 1.55 .2159 1.38 .2418
10 Treatment 72.09 <.0001 68.52 <.0001 150.65 <.0001 32.26 <.0001 108.63 <.0001 115.45 <.0001
Age 3.26 .0736 11.15 .0011 7.22 .0083 0.23 .6300 0.60 .4393 0.64 .4271
Treatment by age 0.83 .3636 0.04 .8433 0.05 .8172 1.00 .3186 0.20 .6556 0.05 .8202
12 Treatment 34.82 <.0001 44.84 <.0001 100.99 <.0001 30.71 <.0001 74.62 <.0001 81.57 <.0001
Age 5.34 .0227 9.44 .0027 12.67 .0006 3.97 .0487 0.13 .7163 0.06 .8065
Treatment by age 0.42 .5170 0.06 .8007 0.00 .9549 1.06 .3058 0.27 .6020 0.13 .7158
13 Treatment 8.29 .0048 34.69 <.0001 38.63 <.0001 10.26 .0018 67.42 <.0001 68.29 <.0001
Age 5.56 .0201 7.40 .0076 9.48 .0026 0.34 .5637 0.03 .8639 0.09 .7587
Treatment by age 0.01 .9293 0.45 .5018 0.45 .5051 2.15 .1458 0.02 .8820 0.02 .8913
LDX: lisdexamfetamine dimesylate; PERMP: Permanent Product Measure of Performance; PERMP-A: PERMP-Attempted; PERMP-C: PERMP-Correct; SKAMP: Swanson,
Kotkin, Agler, M-Flynn, and Pelham; SKAMP-A: SKAMP-Attention; SKAMP-D: SKAMP-Deportment.
*Degrees of freedom (df) = 110 for all analyses except the 7.5-hour postdose time point where df = 109 for all analyses.
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Page 9 of 17with ≥2% difference between sexes in the dose-optimiza-
tion phase included upper abdominal pain (males,
16.3%; females, 12.9%), nausea (males, 7.1%; females,
12.9%), decreased weight (males, 2.0%; females, 6.5%),
headache (males, 18.4%; females, 12.9%), affect lability
(males, 11.2%; females, 6.5%), initial insomnia (males,
6.1%; females, 0.0%), and insomnia (males, 30.6%;
females, 16.1%). During the crossover phase (Table 7),
when receiving LDX, males had a numerically greater
rate of TEAEs (males, 34.5%; females, 28.6%). Differ-
ences (≥2%) in rates of TEAEs between sexes when
receiving LDX in the crossover phase were upper
abdominal pain (males, 2.3%; females, 0.0%), nausea
( m a l e s ,1 . 1 % ;f e m a l e s ,3 . 6 % ) ,h e a d a c h e( m a l e s ,4 . 6 % ;
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Page 10 of 17females, 7.1%), and insomnia (males, 5.7%; females,
0.0%).
Male participants receiving LDX had mean (SD)
changes in weight from baseline of -1.5 (6.8), -2.0 (6.4),
-2.6 (5.7), -2.1 (7.8), and -2.7 (6.2) lb at weeks 1, 2, 3, 4,
and 5/6, respectively. Female participants receiving LDX
had mean (SD) changes in weight from baseline of -1.9
(2.5), -2.3 (1.9), -3.4 (2.0), -3.5 (2.5), and -2.1 (7.0) lb at
weeks 1, 2, 3, 4, and 5/6, respectively.
The overall incidence of TEAEs in each age group was
similar during dose-optimization and crossover phases
(Tables 8 and 9). In the dose-optimization phase, the
incidence rates by dose group at the time of first
occurrence of anorexia in the younger group were
10.4%, 0.0%, and 0.0% and in the older group were 1.2%,
0.0%, and 6.3% for participants receiving 30, 50, and 70
mg/d LDX, respectively. The incidence rates by dose
group at the time of first occurrence of decreased appe-
tite were 37.5%, 17.4%, and 14.3% in the younger group
and 42.0%, 7.8%, and 0.0% in the older group, for parti-
cipants receiving 30, 50, and 70 mg/d LDX, respectively.
In the dose-optimization phase, the incidence rates by
dose group at the time of first occurrence of insomnia
were 31.3%, 13.0%, and 0.0% in the younger group and
1 7 . 3 % ,7 . 8 % ,a n d0 . 0 %i nt h eo l d e rg r o u p ,f o rp a r t i c i -
pants receiving 30, 50, and 70 mg/d LDX, respectively.
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Page 11 of 17Participants aged 6 to 9 years receiving LDX had
mean changes in weight from baseline of -2.5 (6.8), -2.3
(8.1), -3.4 (7.2), -2.2 (9.8), and -2.9 (8.8) lb at weeks 1, 2,
3, 4, and 5/6, respectively. At week 5/6, the mean (SD)
weight loss was -0.7 (6.5), -6.6 (11.8), and -1.4 (1.5) lb
for younger participants receiving 30, 50, 70 mg/d LDX,
respectively. Participants aged 10 to 12 years receiving
LDX had mean (SD) changes in weight from baseline of
-0.8 (5.1), -1.9 (2.0), -2.3 (2.1), -2.6 (2.5), and -2.3 (3.0)
lb at weeks 1, 2, 3, 4, and 5/6, respectively. At week 5/6,
the mean (SD) weight loss of participants was -1.7 (3.2),
-2.3 (2.4), and -3.1 (3.8) lb for older participants receiv-
ing 30, 50, 70 mg/d LDX, respectively.
Discussion
Effects of Sex
The effects of sex on treatment response have not been
thoroughly studied; however, some sex differences in
psychosocial, cognitive, and psychiatric functioning have
been noted and may influence response to treatment.
Psychosocial functioning in boys and girls is generally
similar, but more externalizing behaviors have been
identified in boys [16]. Existing data on sex as a moder-
ating factor in treatment response are mixed [11]. In
addition to the above clinical data, recent studies in ani-
mal models [31] and healthy human adults [32] suggest
the potential for sex differences in the physiologic
response to agents that interact with the dopaminergic
system in the brain. The estrous cycle in female rats
modulates amphetamine-stimulated dopamine release
and other dopaminergic functions in the striatum [31].
Along similar lines, using brain imaging techniques,
M u n r oe ta ld e m o n s t r a t e dt h a tm a l e sh a dg r e a t e r
amphetamine-stimulated dopamine release in the ventral
striatum, anterior putamen, as well as the anterior and
posterior caudate nuclei [32]. Additionally, subjective
positive effects of amphetamine were greater in men
than in women [32]. These preliminary findings are
interesting; however, additional clinical and nonclinical
studies will be necessary to determine whether these dif-
ferences in brain physiology will result in demonstrable
differences in clinical response.
In the current study, significant effects of sex were
noted for SKAMP-D and SKAMP total scores. These
effects were not noted for SKAMP-A, SKAMP quality of
w o r k ,P E R M P - A ,o rP E R M P - C .S i g n i f i c a n tt r e a t m e n t -
by-sex interactions were not seen at the majority of
time points. Females in both placebo and treatment
conditions had lower (ie, improved) scores on all
SKAMP total and subscale scores than did males at all
time points. While receiving placebo, females had higher
(less impaired) scores on the PERMP-A and PERMP-C
than did males receiving placebo. With LDX treatment,
females and males improved and had similar scores on
Table 4 LS Mean (SE) Postdose SKAMP and PERMP Effect Sizes*
Hour SKAMP-D LS Mean
(SE) Effect Size
SKAMP-A LS Mean
(SE) Effect Size
SKAMP Quality of Work LS
Mean (SE) Effect Size
SKAMP Total LS
Mean (SE) Effect
Size
PERMP-A LS Mean
(SE) Effect Size
PERMP-C LS Mean
(SE) Effect Size
1.5 -0.68 (0.14) -0.57 (0.14) -0.23 (0.13) -0.85 (0.15) 0.59 (0.14) 0.74 (0.14)
2.5 -1.41 (0.16) -1.20 (0.16) -1.05 (0.15) -1.89 (0.18) 1.28 (0.16) 1.34 (0.16)
5.0 -1.44 (0.16) -1.19 (0.16) -1.24 (0.16) -1.90 (0.18) 1.40 (0.16) 1.44 (0.16)
7.5 -1.41 (0.16) -1.27 (0.16) -1.17 (0.16) -1.94 (0.19) 1.53 (0.17) 1.56 (0.17)
10.0 -1.12 (0.15) -1.11 (0.15) -0.77 (0.14) -1.64 (0.17) 1.39 (0.16) 1.44 (0.16)
12.0 -0.78 (0.14) -0.89 (0.15) -0.75 (0.14) -1.35 (0.16) 1.15 (0.15) 1.21 (0.16)
13.0 -0.38 (0.14) -0.80 (0.14) -0.44 (0.14) -0.84 (0.14) 1.10 (0.15) 1.11 (0.15)
Mean
† -1.73 (0.18) -1.54 (0.17) -1.73 (0.18) -2.41 (0.21) 1.78 (0.18) 1.83 (0.18)
LS: least squares; PERMP: Permanent Product Measure of Performance; PERMP-A: PERMP-Attempted; PERMP-C: PERMP-Correct; SE: standard error; SKAMP:
Swanson, Kotkin, Agler, M-Flynn, and Pelham; SKAMP-A: SKAMP-Attention; SKAMP-D: SKAMP-Deportment.
*Negative SKAMP effect sizes indicate improvement with LDX. Positive PERMP effect sizes indicate improvement with LDX.
†Mean SKAMP and PERMP scores across the day were calculated employing the model-based calculations using all measures for all participants at all time points
across the day.
Table 5 Postdose SKAMP Mean (SE) Effect Size* by Optimized Dose
LDX Dose Group SKAMP-D SKAMP-A SKAMP Quality of Work SKAMP Total
30 mg/d (n = 46) -0.85 (0.23) -0.67 (0.22) -0.94 (0.23) -1.13 (0.24)
50 mg/d (n = 47) -0.86 (0.22) -0.80 (0.22) -1.14 (0.24) -1.18 (0.24)
70 mg/d (n = 20) -1.14 (0.36) -0.98 (0.35) -0.83 (0.34) -1.24 (0.37)
LDX: lisdexamfetamine dimesylate; SE: standard error; SKAMP: Swanson, Kotkin, Agler, M-Flynn, and Pelham; SKAMP-A: SKAMP-Attention; SKAMP-D: SKAMP-
Deportment.
*Negative effect sizes indicate improvement with LDX.
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Page 12 of 17PERMP-A and PERMP-C. The lack of consistent treat-
ment-by-sex interactions indicated that both males and
females responded well to LDX. Further, the results of
this analysis support the efficacy of LDX from 1.5 hours
to 13 hours postdose in both male and female partici-
pants. The duration of effect of LDX does not seem to
differ between males and females. Although there
appeared to be greater separation between the LDX and
placebo conditions among males, females generally
showed less impairment prior and subsequent to dosing
than did males in the same treatment condition. The
beneficial effects of LDX observed may have been
restricted by the limited impairment seen in females
overall (ie, a floor effect). This finding is similar to that
in the COMACS study [14], an analog classroom study
of male and female children that used typical laboratory
school measures to assess once-daily methylphenidate vs
placebo but that likewise was not powered statistically
to specifically measure student sex-based differences in
stimulant treatment.
However, the results of the post hoc treatment-by-sex
analysis presented here differs from the COMACS
study, a trial with a similar double-blind, analog class-
room design and a similar participant age profile, in
which efficacy at early vs later time points differed
between males and females [14]. Additionally, statistical
analysis of SKAMP scores in the placebo cohort showed
differences at predose and most postdose time points
between males and females [14]. Interestingly, differ-
ences between sexes were not apparent when assessing
PERMP scores in the COMACS study [14]. While no
Table 6 TEAEs by sex in the dose-optimization phase
while receiving LDX with an incidence of ≥10% in the
dose-optimization and/or crossover phase
AE-Preferred Term Dose-Optimization Phase
Males Females
(n = 98) (n = 31)
n (%) n (%)
Any AE 83 (84.7) 27 (87.1)
Abdominal pain upper 16 (16.3) 4 (12.9)
Affect lability 11 (11.2) 2 (6.5)
Decreased appetite 47 (48.0) 14 (45.2)
Headache 18 (18.4) 4 (12.9)
Insomnia 30 (30.6) 5 (16.1)
Irritability 16 (16.3) 5 (16.1)
Nausea 7 (7.1) 4 (12.9)
For tables 6-9: TEAEs were assigned to either the open-label dose-
optimization phase or the double-blind crossover phase of the study and
were summarized separately. TEAEs that continued uninterrupted from the
dose-optimization to the crossover phase without a change in severity were
counted only in the dose-optimization phase category. TEAEs with a change
in severity across phases or that resolved and then restarted in the crossover
phase were counted both in the dose-optimization and crossover arms. TEAEs
for which a missing or incomplete start date made it impossible to determine
in which phase of the study they started were counted as starting in the
dose-optimization phase.
Table 7 TEAEs by sex in the crossover phase while
receiving LDX with an incidence of ≥10% in the
dose-optimization and/or crossover phase
AE-Preferred Term Crossover Phase
Males Females
(n = 87) (n = 28)
n (%) n (%)
Any AE 30 (34.5) 8 (28.6)
Abdominal pain upper 2 (2.3) 0 (0.0)
Affect lability 0 (0.0) 0 (0.0)
Decreased appetite 5 (5.7) 2 (7.1)
Headache 4 (4.6) 2 (7.1)
Insomnia 5 (5.7) 0 (0.0)
Irritability 1 (1.1) 0 (0.0)
Nausea 1 (1.1) 1 (3.6)
Table 8 TEAEs by age group in the dose-optimization
phase while receiving LDX with an incidence of ≥10% in
the dose-optimization and/or crossover phase
AE-Preferred Term Dose-Optimization Phase
6 to 9 year olds 10 to 12 year olds
(n = 48) (n = 81)
n (%) n (%)
Any AE 43 (89.6) 67 (82.7)
Abdominal pain upper 8 (16.7) 12 (14.8)
Affect lability 7 (14.6) 6 (7.4)
Anorexia 5 (10.4) 2 (2.5)
Decreased appetite 23 (47.9) 38 (46.9)
Headache 9 (18.8) 13 (16.0)
Insomnia 17 (35.4) 18 (22.2)
Irritability 7 (14.6) 14 (17.3)
Table 9 TEAEs by age group in the crossover phase
while receiving LDX with an incidence of ≥10% in the
dose-optimization and/or crossover phase
AE-Preferred Term Crossover Phase
6 to 9 year olds 10 to 12 year olds
(n = 42) (n = 73)
n (%) n (%)
Any AE 16 (38.1) 22 (30.1)
Abdominal pain upper 1 (2.4) 1 (1.4)
Affect lability 0 (0.0) 0 (0.0)
Anorexia 0 (0.0) 0 (0.0)
Decreased appetite 2 (4.8) 5 (6.8)
Headache 2 (4.8) 4 (5.5)
Insomnia 3 (7.1) 2 (2.7)
Irritability 1 (2.4) 0 (0.0)
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Page 13 of 17statistical analysis was performed here to assess differ-
ences between sexes for the placebo cohort alone, the
current data similarly appear to show differential charac-
teristics between sexes in the placebo cohort for
SKAMP but not PERMP measures. While these sex dif-
ferences are intriguing, any consideration of cause
would be speculative in nature. These findings indicate
a need for continued close examination of differential
presentation of ADHD symptoms and symptom clusters
in females and males.
Although the distribution of participants by sex and
racial group was similar, there were some differences
between the current study and the COMACS study in
participant demographic characteristics. Mean age was
slightly higher in the current study than in the
COMACS study (10.1 vs 9.58 years), and all participants
in the current study had combined-type ADHD, whereas
approximately 82% in the COMACS study had com-
bined-type ADHD [14]. Although the application of dif-
ferent entry criteria (ADHD-RS-IV scores ≥28 vs no
severity cutoff) and baseline ADHD assessment mea-
sures (ADHD-RS-IV vs Swanson, Nolan and Pelham
s c a l e[ S N A P ] )i nt h ec u r r e n ts t u d ya n dt h eC O M A C S
study, respectively, make it difficult to specifically assess
similarity in baseline ADHD symptom severity [14],
overall SNAP baseline inattention and overactivity/
impulsivity scores between 1.09 and 1.28 suggest that
ADHD severity in the COMACS study population may
have been somewhat less than the severity in the cur-
rent study (mean ADHD-RS-IV baseline score was 42.4).
Effects of age
Significant effects for age were noted in SKAMP-D,
SKAMP-A, and SKAMP total scores, but not for
PERMP-A or PERMP-C measures. Significant treat-
ment-by-age interactions were not seen at the majority
of time points for both SKAMP and PERMP measures.
Both age groups responded to treatment. Older children
in both the placebo and the treatment condition groups
had lower SKAMP total and subscale scores than did
younger children at predose and in a majority of the
measured postdose time points. These findings of lower
scores suggesting less impairment in older than younger
children are in general agreement with previous findings
that highlight age-dependent decline of symptoms and
age-dependent changes in the functional expression of
symptoms of ADHD [33-35]. The duration of effect of
LDX does not seem to differ between age groups.
Effect size
From 1.5 to 13 hours postdose, the effect size of LDX
for the primary efficacy variable, SKAMP-D, was med-
ium to large at most postdose time points, as was the
mean effect size over the course of the day. It should be
noted that overall mean effect sizes across the day for
SKAMP-D and the other SKAMP and PERMP measures
were calculated in the model-based system and included
all appropriate assessment values for all time points, so
variance of these calculated means is commensurately
small. The mean overall raw effect sizes for all opti-
mized doses of LDX (median optimized LDX dose was
5 0m g / d )w e r em e d i u mt ol a r g ef o rS K A M P - D ,
SKAMP-A, SKAMP quality of work, and SKAMP total
scores. These results are not indicative of dose response
because participants were not randomized to a dose
group but rather were clinically titrated to LDX doses
studied in the double-blind portion of the study. Thus,
in the analog classroom setting, LDX was effective in
reducing ADHD symptoms of deportment and attention
from 1.5 to 13 hours postdose based on optimized dos-
ing with mostly medium to large effect sizes for a broad
array of assessments, including clinician observations,
classroom behavior, and test of math performance.
Large treatment effect sizes were also observed for
DSM-IV-TR–defined ADHD symptoms as assessed by
ADHD-RS-IV total and subscores. These findings are
consistent with a previous report that demonstrated
similarly large ADHD-RS-IV effect sizes (1.39, 1.42, and
1.73 for 30, 50, and 70 mg/d LDX, respectively) in chil-
dren with ADHD receiving LDX in a clinical trial with a
longitudinal design [36].
Meta-analyses of multiple studies have concluded that
effect sizes for the treatment of ADHD average 0.91 to
0.95 for stimulant agents [24,37]. A randomized, double-
blind, placebo-controlled study of the MPH-ER formula-
tion (20, 40, or 60 mg/d) and OROS-MPH formulation
(18, 36, or 54 mg/d) in the treatment of ADHD in chil-
dren (6-12 years of age) examined effect sizes at various
time points. Dosing was based on preexisting methyl-
phenidate dosing. Effect sizes for MPH-ER as measured
by SKAMP-D ranged from 0.06 (at 12 hours postdose)
to 0.89 (at 3 hours postdose). Effect sizes for OROS-
MPH ranged from 0.25 (at 12 hours postdose) to 0.66
(at 6 hours postdose) [6]. A placebo-controlled, double-
blind, multiple-crossover study of methylphenidate
(approximately 0.3 mg/kg/d) that studied the same par-
ticipants as children and as adolescents in a summer
treatment program reported an overall effect size, the
product of 12 different measures (including IOWA Con-
ners Rating Scale-counselor and IOWA Conners Rating
Scale-teacher ratings, assessment of classwork completed
and correct, and behavioral assessments of rule viola-
tions and other negative and positive behaviors), of 0.82
in children and 0.59 in adolescents [38].
Small to medium effect sizes favoring placebo were
observed at predose time points for SKAMP-A and
SKAMP-D, and large effect sizes at predose favoring
placebo were observed for SKAMP quality of work,
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Although many factors may have contributed to this
observation, residual drug from the previous treatment
day may have played a role in this finding as has been
seen in another study with an amphetamine-based long-
acting stimulant [39]. Pharmacokinetic data showing
residual plasma levels were measurable prior to dosing
with long-acting stimulants [40,41]. The impact of these
pretreatment differences on the ultimate relationship
between postdose LDX and placebo responses is
unclear.
Overall incidence of TEAEs in this study has been
described in detail [10] and is generally similar to that
reported in other pediatric studies of LDX [8] and other
long-acting stimulants [9,42,43] where active treatment
was begun after a washout period for prior treatments.
A consistent pattern of greater incidence of TEAEs in
either age group did not emerge. The incidence of anor-
exia was higher in the younger group than in the older
group. Although the incidence of decreased appetite was
roughly equivalent, the greater incidence of weight
decrease as a reported AE in participants aged 6 to 9
years may be related in part to the higher incidence of
anorexia in this age group. The incidence of insomnia
was 35.4% in the younger group and 22.2% in the older
group. When assessed by sex,o v e r a l li n c i d e n c eo f
TEAEs was similar between boys and girls. For some
commonly reported TEAEs with LDX treatment (eg,
insomnia, headache, and affect lability), incidence was
somewhat higher in boys than in girls.
Limitations
The current analysis has some limitations. As these are
p o s th o ca n a l y s e sa n dn o tp a r to ft h eap r i o r ip l a n n e d
analyses, they were not adequately powered to make
direct comparisons of subgroup differences in efficacy
variables or AE incidence. The relatively small group
sizes and the approximately 3:1 ratio of boys to girls in
the study make it difficult to form firm conclusions
regarding possible sex effects. It should be noted, how-
ever, that this sex disparity is improved from previous
trials that have shown male-to-female ratios as high as
9:1 [17,44-46]. This improvement may be attributable to
better identification and diagnosis of female individuals
with ADHD.
While the TEAE tables may appear to show fewer
TEAEs during the crossover phase than in the preceding
dose-optimization phase, one should consider the rela-
tive duration of treatment exposure during the 2 phases,
as well as the manner in which TEAEs were reported.
TEAE incidence rates are based on newly occurring
events at each weekly assessment during the dose-opti-
mization and crossover phases. As such, continuing
TEAEs would only appear at the assessment in which
they were first reported. Similarly, when considering the
relative incidence of TEAEs during the dose-optimiza-
tion phase, readers should remember that TEAEs
reported by dose may be related to timing of dose esca-
lation during the optimization process rather than to
dose-dependent effects. Thus, those TEAEs occurring
during the first week of dose-optimization treatment
would be reported for 30 mg/d LDX since all partici-
pants began dosing at 30 mg/d LDX; those TEAEs first
occurring during the second week would be ascribed to
either 30 mg/d or 50 mg/d LDX, and so on. Based on
the available data from this study, dose dependence of
TEAEs cannot be assessed.
Conclusions
Although the study was not adequately powered to
make direct comparisons of subgroups, the results of
this analysis support the efficacy of LDX from 1.5 hours
t o1 3h o u r sp o s t d o s ei nb o t hb o y sa n dg i r l sw i t hm e d -
ium to large mean effect sizes across the day.
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